



























66. Joos B, and al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. *Proc. Natl. Acad. Sci* 105 (2008): 16725–16730
67. Demarchi F, d'Adda di Fagagna F, Falaschi A, Giacca M. Activation of transcription factor NF-B by the Tat protein of human immunodeficiency virus type 1. *J. Virol* 70 (1996): 4427–4437.
68. Demarchi F, Gutierrez MI, Giacca M. 1999. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-B through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. *J. Virol* 73 (1999): 7080–7086.
69. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. *Proc. Natl. Acad. Sci* 95 (1998): 13519–13524.
70. Treand C, and al. Requirement for SWI/SNF chromatin-remodeling complex in Tat-mediated activation of the HIV-1 promoter. *EMBO J* 25 (2006): 1690–1699.
71. Vardabasso C, Manganaro L, Lusic M, Marcello A, Giacca M. The histone chaperone protein Nucleosome Assembly Protein-1 (hNAP-1) binds HIV-1 Tat and promotes viral transcription. *Retrovirology* 5 (2008): 5- 8
72. Barboric M, and al. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. *Nucleic Acids Res* 35 (2007): 2003– 2012
73. Muniz L, Egloff S, Ughy B, Jady BE, Kiss T. Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat. *PLoS Pathog.* 6 (2010): e1001152.
74. Daniel A., Donahue, jörn D. Kuhl, Richard D., Sloan, and Mark A. The Viral Protein Tat Can Inhibit the Establishment of HIV-1 Latency. *Journal of Virology* 86 (2012): 3253–3263
75. Siliciano, J.D.; Kajdas, J.; Finzi, D.; Quinn, T.C.; Chadwick, K.; Margolick, J.B.; Kovacs, C.; Gange, S.J.; Siliciano, R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. *Nat. Med* 9 (2003): 727–728.
76. Baxter, A.E.; Niessl, J.; Fromentin, R.; Richard, J.; Porichis, F.; Charlebois, R.; Massanella, M.; Brassard, N.; Alshafiq, N.; Delgado, G.-G.; and al. Single-cell characterization of viral translation-competent reservoirs in HIV-infected individuals. *Cell Host Microbe* 20 (2016): 368–380.
77. Colby, D.J.; Trautmann, L.; Pinyakorn, S.; Leyre, L.; Pagliuzza, A.; Kroon, E.; Rolland, M.; Takata, H.; Buranapraditkun, S.; Intasan, J.; and al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. *Nat. Med* 24 (2018): 923–926.
78. Goldstein, G. HIV-1 Tat protein as a potential AIDS vaccine. *Nat. Med* 2 (1996): 960–964.
79. Shi, J.; Manolikakes, G.; Yeh, C.H.; Guerrero, C.A.; Shenvi, R.A.; Shigehisa, H.; Baran, P.S. Scalable synthesis of cortistatin A and related structures. *J. Am. Chem. Soc* 133 (2011): 8014–8027.
80. Mediouni, S.; Chinthalapudi, K.; Ekka, M.K.; Usui, I.; Jablonski, J.A.; Clementz, M.A.; Mousseau, G.; Nowak, J.; Macherla, V.R.; Beverage, J.N. and al. Didehydrocortistatin A inhibits HIV-1 by specifically binding to the unstructured basic region of Tat. *MBio* 10 (2019): e02662-18.
81. Reiss, P. and al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. *J. Med. Virol* 30 (1990): 163-168.
82. Neuveut, C. and Jeang, K.T. Recombinant HIV-1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. *J. Virol* 70 (1996): 5572-5581.
83. Ensoli B, Moretti S, Borsetti A, et al. new insights into pathogenesis point to HIV-1 Tat as a key vaccine target. *Arch Virol* 11 (2021): 2955-2974.
84. Paolo Monini, Antonella Tripiciano, Orietta Picconi, Anna Casabianca, Chiara Orland, Sonia Moretti, Vittorio Francavilla, Angela Arancio, Giovanni Paniccia, Massimo Campagna, Stefania Bellino, Marianna Meschiari, Silvia Nozza, Laura Sighinolfi, Alessandra Latini, Antonio Muscatello, Annalisa Saracino, Massimo Di Pietro, Massimo Galli, Aurelio Cafaro, Mauro Magnani Fabrizio Ensoli and Barbara Ensoli. Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study Cecilia Sgadari. *Frontiers in Immunology* 10 (2019): 1-19.
85. Aurelio Cafaro and Barbara Ensoli. HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine, *Expert Review of Vaccines* 21 (2022): 1243-1253.